| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $10.8M | — |
| R&D Expense | $138.1M | +868.4% |
| SG&A Expense | $25.4M | +39.1% |
| Operating Income | -$152.6M | -281.2% |
| Pre-tax Income | -$151.9M | — |
| Income Tax | $2.0M | — |
| Net Income | -$153.9M | -306.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $213.2M | +1888.7% |
| Accounts Receivable | $18.0M | — |
| Current Assets | $236.7M | +2033.7% |
| Total Assets | $240.3M | +2066.5% |
| Current Liabilities | $36.1M | +524.3% |
| Total Liabilities | $37.3M | +545.2% |
| Stockholders' Equity | $203.0M | +3720.6% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$71.5M | -130.0% |
| Capital Expenditures | $919K | +9115.8% |
| Investing Cash Flow | -$72.9M | — |
| Financing Cash Flow | $323.0M | — |
| Free Cash Flow | -$72.5M | -132.9% |